| 雄激素受体在乳腺癌中的研究进展 |
| |
| 引用本文： | 钟镇铧,房林. 雄激素受体在乳腺癌中的研究进展[J]. 同济大学学报(医学版), 2017, 38(2): 120-124 |
| |
| 作者姓名： | 钟镇铧 房林 |
| |
| 作者单位： | 同济大学附属第十人民医院甲状腺乳腺外科,上海 200072,同济大学附属第十人民医院甲状腺乳腺外科,上海 200072,同济大学附属第十人民医院甲状腺乳腺外科,上海 200072 |
| |
| 基金项目： | 国家自然科学基金(81272240) |
| |
| 摘 要： | 大约70%的乳腺癌表达雄激素受体(androgen receptor, AR),研究数据表明雄激素受体可能在乳腺癌的发生机制中起重要作用,在某些难治性乳腺癌亚型中可以作为一种治疗靶点,比如三阴性乳腺癌(Triple-Negative Breast Cancer, TNBC)。临床上AR作为预后标志物及其在肿瘤中的功能作用尚不完全清楚。目前,乳腺癌中AR的研究已成为一个新的热点,本文就AR在乳腺癌中的研究现状作一综述。
|
| 关 键 词： | 雄激素受体 乳腺癌 三阴性乳腺癌 |
| 收稿时间： | 2015-12-07 |
Progression on androgen receptor in breast cancer |
| |
| Affiliation: | Dept. of Breast and Thyroid Surgery, Tenth People''s Hospital, Tongji University, Shanghai 200072, China,Dept. of Breast and Thyroid Surgery, Tenth People''s Hospital, Tongji University, Shanghai 200072, China and Dept. of Breast and Thyroid Surgery, Tenth People''s Hospital, Tongji University, Shanghai 200072, China |
| |
| Abstract: | About 70% of human breast cancers express androgen receptor(AR). Studies suggest that AR may play a role in pathogenesis of breast cancer and serve as a therapeutic target in certain types of breast cancer, such as triple-negative breast cancer(TNBC). Although this is an active research area, the clinical significance of AR as a prognostic marker and its role in tumorigenesis is unclear yet. At present, the research of AR in breast cancer becomes a new hotspot. This article reviews the research progress of the relationship between AR and breast cancer. |
| |
| Keywords: | |
|
| 点击此处可从《同济大学学报(医学版)》浏览原始摘要信息 |
|
点击此处可从《同济大学学报(医学版)》下载全文 |
|
